Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest announcement is out from Recursion Pharmaceuticals ( (RXRX) ).
In a strategic move, the Company finalized its acquisition of Exscientia, making it a wholly-owned subsidiary. The transaction involved exchanging Exscientia shares for the Company’s Class A Common Stock, leading to Exscientia’s delisting from Nasdaq. Notable executive changes followed, with Franziska Michor joining the Company’s board, Ben Taylor becoming CFO, and Christopher Gibson assuming the role of President alongside his CEO duties. Additionally, operational changes and a new equity incentive plan were announced, signaling a fresh phase of growth and innovation.
Learn more about RXRX stock on TipRanks’ Stock Analysis page.
